ClinConnect ClinConnect Logo
Search / Trial NCT03065543

Hyperlipidemia Therapy TERCET Zabrze Registry

Launched by SILESIAN CENTRE FOR HEART DISEASES · Feb 22, 2017

Trial Information

Current as of July 21, 2025

Recruiting

Keywords

Hyperlipidemias Secondary Prevention High Risk Patients Very High Risk Patients

ClinConnect Summary

The Hyperlipidemia Therapy TERCET Zabrze Registry is a clinical trial designed to study the effectiveness of treatments aimed at lowering cholesterol levels in patients who have high cholesterol and are at risk for heart problems. The researchers want to see if these treatments can help patients reach specific cholesterol goals after one year. For instance, they will check if patients with very high risk can lower their LDL cholesterol (often called "bad" cholesterol) to less than 70 mg/dL, and if those at high risk can lower it to less than 100 mg/dL. The study will also look at how well these treatments work over the years and how they relate to the severity of heart artery issues.

To be eligible for this trial, patients must have coronary artery disease along with high cholesterol. Unfortunately, those without coronary artery disease cannot participate. If you join the study, you will be monitored over time to see how well the lipid-lowering therapies work for you. This trial is currently recruiting participants of all genders, aged 65 and older. By participating, you could help researchers understand better ways to manage cholesterol and improve heart health for many people.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • All patients with coronary artery disease with hyperlipidemia
  • Exclusion Criteria:
  • No coronary artery disease

About Silesian Centre For Heart Diseases

The Silesian Centre for Heart Diseases is a leading clinical research institution dedicated to advancing cardiovascular medicine through innovative research and clinical trials. With a strong commitment to improving patient outcomes, the Centre focuses on the development and evaluation of novel therapies and interventions for heart diseases. Its multidisciplinary team of experienced clinicians and researchers collaborates with national and international partners to ensure the highest standards of scientific rigor and ethical conduct in all studies. By prioritizing patient safety and efficacy, the Silesian Centre for Heart Diseases aims to contribute significantly to the field of cardiology and enhance the quality of care for patients worldwide.

Locations

Zabrze, Upper Silesia, Poland

Patients applied

0 patients applied

Trial Officials

Mariusz Gasior, prof.MD,PhD

Principal Investigator

3rd Department of Cardiology, SMDZ in Zabrze, Medical University of Silesia, Katowice, Poland

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials